How is it still winter?And why am I still ill?” Flu, Covid and RSV are circulating, while vomiting bugs might also catch you ...

DF-003 is the first ALPK1 inhibitor to successfully complete a first-in-human Phase 1 study and has now entered a Phase 1b clinical trial in patients with ROSAH syndrome (NCT06395285), where it is ...

Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company focused on delivering a new class of innovative immunotherapies for patients with cancer and other incurable diseases, announced today that a late ...

Targeted therapies have been moved forward in the treatment of both pemphigus and pemphigoid diseases, a factor behind an urgency for rapid diagnosis.

NLRP3 is a validated anti-inflammatory target that mediates the release of proinflammatory cytokines IL-1β and IL-18, and ISM5059 targets systemic inflammatory conditions by targeting NLRP3 and ...

Your body might be sending you hints about your health.

NLRP3 is a validated anti-inflammatory target that mediates the release of proinflammatory cytokines IL-1β and IL-18, and ISM5059 targets systemic inflammatory conditions by targeting NLRP3 and ...

HONG KONG, Jan. 29, 2026 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") today announced positive topline results from the Phase III open-label study (NCT06248008) evaluating denifanstat ...

Dr. McDonough brings global company-building, commercial strategy, and R&D leadership experience to the Company ahead of key clinical ...

Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing and commercializing ...

YOU can’t beat a steaming hot cup of tea first thing in the morning. Not only does the brew soothe and perk you up, it’s also ...